Edwards Lifesciences VP plans 2027 retirement

Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027.

Rhea-AI Filing Summary

Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027. The board will begin a selection process promptly to identify a successor, with a transition of duties expected during 2027.

The company also states that Mr. Bobo is expected to remain with Edwards as a consultant through the end of 2027, providing continuity during and after the leadership transition.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Planned retirement timing: mid-year 2027 Consultancy period end: end of 2027 Form 8-K date: August 25, 2026 +1 more

4 metrics

Planned retirement timing mid-year 2027 Timing of retirement of Corporate Vice President, Strategy and Corporate Development

Consultancy period end end of 2027 Expected end of Donald E. Bobo, Jr.’s consultancy with the company

Form 8-K date August 25, 2026 Date of the reported event under the Exchange Act

Signature date August 28, 2026 Date the report was signed by the Chief Financial Officer

Key Terms

Form 8-K, Section 13 or 15(d) of the Securities Exchange Act of 1934, emerging growth company, Section 12(b) of the Act

4 terms

Form 8-K regulatory

"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

Section 13 or 15(d) of the Securities Exchange Act of 1934 regulatory

"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"

emerging growth company regulatory

"405) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 12(b) of the Act regulatory

"Securities registered pursuant to Section 12(b) of the Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership change did Edwards Lifesciences (EW) disclose in this Form 8-K?

Edwards Lifesciences disclosed that Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, has decided to retire by mid-year 2027. The company plans to identify a successor and transition his duties during 2027, with Mr. Bobo remaining as a consultant through year-end 2027.

When will Donald E. Bobo, Jr. retire from Edwards Lifesciences (EW)?

Donald E. Bobo, Jr. has informed Edwards Lifesciences that he plans to retire by mid-year 2027. The company expects a transition of his duties during 2027 as part of the succession process.

Will Donald E. Bobo, Jr. remain involved with Edwards Lifesciences (EW) after retirement?

Yes. Edwards Lifesciences reports that Donald E. Bobo, Jr. is expected to remain as a consultant through the end of 2027, supporting the company following his retirement and during the leadership transition.

What role is affected by the announced retirement at Edwards Lifesciences (EW)?

The affected role is Corporate Vice President, Strategy and Corporate Development. Donald E. Bobo, Jr., who holds this position, has notified Edwards Lifesciences of his decision to retire by mid-year 2027.

How will Edwards Lifesciences (EW) handle succession for Donald E. Bobo, Jr.’s role?

Edwards Lifesciences states that a selection process will begin promptly to identify a successor to Donald E. Bobo, Jr. The company expects this process to result in a transition of duties during 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:16 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:15 PM EDT Learn about SEC filing dates

0001099800false00010998002026-08-252026-08-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2026

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-15525

36-4316614

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $1.00 per share			EW			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027. Mr. Bobo is also expected to remain as a consultant with the Company through the end of 2027.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						EDWARDS LIFESCIENCES CORPORATION
						By:			/s/ Theodora Mistras
									Theodora Mistras
Date: August 28, 2026									Chief Financial Officer

3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB